



Universiteit  
Leiden  
The Netherlands

## Early phase clinical drug development for HPV-induced disorders: novel tools and treatments

Rijsbergen, M.

### Citation

Rijsbergen, M. (2020, February 19). *Early phase clinical drug development for HPV-induced disorders: novel tools and treatments*. Retrieved from <https://hdl.handle.net/1887/85448>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/85448>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/85448> holds various files of this Leiden University dissertation.

**Author:** Rijsbergen, M.

**Title:** Early phase clinical drug development for HPV-induced disorders: novel tools and treatments

**Issue Date:** 2020-02-19

# STELLINGEN

behorende bij het proefschrift

## Early phase clinical drug development for HPV-induced disorders: novel tools and treatments

1. In clinical research caliper measurements of HPV-induced lesions should be replaced by 3D photography measurements. (dit proefschrift)
2. Measuring treatment adherence using an electronic diary during clinical trials assists to answer the question whether the drug reaches the site of action. (dit proefschrift)
3. Electronic diaries with reminder function can improve treatment adherence in clinical trials. (dit proefschrift)
4. Combining digoxin and furosemide in a gel exerts an antiviral effect that translates in an effective treatment for cutaneous warts. (dit proefschrift)
5. Topical omiganan reduces the HPV load in anogenital warts, but shows no clinical efficacy as monotherapy. (dit proefschrift)
6. Drugs don't work in patients who don't take them. (C. Everett Koop, general surgeon)
7. Objective and accurate tools to evaluate treatments are as indispensable as effective drugs.
8. Measuring HPV load in swabs is the ideal non-invasive disease specific biomarker that can be used longitudinally for the same lesion.
9. Measuring the dimensions of vulvar HSIL would benefit from targeted visualization.
10. De hoop op effectiviteit van een middel in een studie kan je als onderzoeker op het verkeerde pad zetten; 'The easiest person to fool is yourself'. (Richard Feynman, 1918-1988)
11. Een goede dokter en klinisch onderzoeker zijn begint met luisteren naar de patiënt.

Melanie Rijsbergen – 19 februari 2020